Modifiable prognostic factors of high societal costs among people on sick leave due to musculoskeletal disorders: findings from an occupational cohort study.

HEALTH ECONOMICS Musculoskeletal disorders Observational Study

Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
01 Mar 2024
Historique:
medline: 3 3 2024
pubmed: 3 3 2024
entrez: 2 3 2024
Statut: epublish

Résumé

The objective was to identify modifiable prognostic factors of high societal costs among people on sick leave due to musculoskeletal disorders, and to identify modifiable prognostic factors of high costs related to separately healthcare utilisation and productivity loss. A prospective cohort study with a 1-year follow-up. A total of 549 participants (aged 18-67 years) on sick leave (≥ 4 weeks) due to musculoskeletal disorders in Norway were included. The primary outcome was societal costs aggregated for 1 year of follow-up and dichotomised as high or low, defined by the top 25th percentile. Secondary outcomes were high costs related to separately healthcare utilisation and productivity loss aggregated for 1 year of follow-up. Healthcare utilisation was collected from public records and included primary, secondary and tertiary healthcare use. Productivity loss was collected from public records and included absenteeism, work assessment allowance and disability pension. Nine modifiable prognostic factors were selected based on previous literature. Univariable and multivariable binary logistic regression analyses were performed to identify associations (crude and adjusted for selected covariates) between each modifiable prognostic factor and having high costs. Adjusted for selected covariates, six modifiable prognostic factors associated with high societal costs were identified: pain severity, disability, self-perceived health, sleep quality, return to work expectation and long-lasting disorder expectation. Depressive symptoms, work satisfaction and health literacy showed no prognostic value. More or less similar results were observed when high costs were related to separately healthcare utilisation and productivity loss. Factors identified in this study are potential target areas for interventions which could reduce high societal costs among people on sick leave due to musculoskeletal disorders. However, future research aimed at replicating these findings is warranted. NCT04196634, 12 December 2019.

Identifiants

pubmed: 38431296
pii: bmjopen-2023-080567
doi: 10.1136/bmjopen-2023-080567
doi:

Banques de données

ClinicalTrials.gov
['NCT04196634']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e080567

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Rikke Munk Killingmo (RM)

Department of Rehabilitation Science and Health Technology, Oslo Metropolitan University, Oslo, Norway rikke@oslomet.no.

Anne Therese Tveter (AT)

Center for treatment of rheumatic and musculoskeletal diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.

Are Hugo Pripp (AH)

Department of Rehabilitation Science and Health Technology, Oslo Metropolitan University, Oslo, Norway.
Oslo Centre of Biostatistics and Epidemiology Research Support Services, Oslo University Hospital, Oslo, Norway.

Alexander Tingulstad (A)

Department of Rehabilitation Science and Health Technology, Oslo Metropolitan University, Oslo, Norway.

Esther Maas (E)

Department of Health Sciences, Vrije University Amsterdam, Amsterdam, The Netherlands.
The Amsterdam Movement Sciences Research Institute, Amsterdam, The Netherlands.

Tarjei Rysstad (T)

Department of Rehabilitation Science and Health Technology, Oslo Metropolitan University, Oslo, Norway.

Margreth Grotle (M)

Department of Rehabilitation Science and Health Technology, Oslo Metropolitan University, Oslo, Norway.
Department of Research and Innovation, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.

Classifications MeSH